H-YLQPR^TFLL-OH
Ref. 3D-PP49306
| Undefined size | To inquire |
Product Information
Peptide H-YLQPR^TFLL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using H-YLQPR^TFLL-OH include the following: Predicting SARS-CoV-2 epitope-specific TCR recognition using pre-trained protein embeddings Y Han, A Lee - bioRxiv, 2021 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/2021.11.17.468929.abstract Integrative immunoinformatics paradigm for predicting potential B-cell and T-cell epitopes as viable candidates for subunit vaccine design against COVID-19 VR Sarma, FA Olotu , MES Soliman - biomedical journal, 2021 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S2319417021000457 Three doses of BNT162b2 COVID-19 mRNA vaccine establish long-lasting CD8+ T cell immunity in CLL and MDS patients SPA Hernandez, DS Hersby, KK Munk - Frontiers in , 2023 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2022.1035344/full Three-doses of BNT162b2 COVID-19 mRNA vaccine establishes long-lasting CD8+ T cell immunity in CLL and MDS patients SP Amaya Hernandez, DS Hersby, KK Munk - bioRxiv, 2022 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/2022.05.13.491706.abstract Identification of a promiscuous conserved CTL epitope within the SARS-CoV-2 spike protein S Jiang, S Wu, G Zhao, Y He, X Guo - Emerging microbes & , 2022 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/22221751.2022.2043727 Virus induced lymphocytes (VIL) as a novel viral antigen-specific T cell therapy for COVID-19 and potential future pandemics R Sivapalan, J Liu, K Chakraborty, E Arthofer - Scientific Reports, 2021 - nature.comhttps://www.nature.com/articles/s41598-021-94654-y A Novel Cell Therapy for COVID-19 and Potential Future Pandemics: Virus Induced Lymphocytes (VIL) R Sivapalan, J Liu, K Chakraborty, E Arthofer - bioRxiv, 2020 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/2020.11.26.400390.abstract Identification of a potential mRNA-based vaccine candidate against the SARS-CoV-2 spike glycoprotein: A reverse vaccinology approach OA Durojaye , DM Sedzro , MO Idris , AA Yekeen - , 2022 - Wiley Online Libraryhttps://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/slct.202103903 SARS-CoV-2 modulates NK cell responses via induction of HLA-E and triggers expansion of adaptive NK cells during acute infection MZ Hasan , M Claus, N Kruger, S Reusing, E Gall - bioRxiv, 2024 - biorxiv.orghttps://www.biorxiv.org/content/10.1101/2024.03.04.583260.abstract SARS-CoV-2 infection induces adaptive NK cell responses by spike protein-mediated induction of HLA-E expression MZ Hasan , M Claus, N Kruger, S Reusing - Emerging Microbes & , 2024 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/22221751.2024.2361019 Phenotypic and Functional Characterization of Natural Killer Cell Receptors in Human and Rhesus Macaque MZ Hasan - 2024 - ediss.uni-goettingen.dehttps://ediss.uni-goettingen.de/handle/11858/15105 Rapid Screen for Antiviral T-Cell Immunity with Nanowire Electrochemical Biosensors M Nami , P Han , D Hanlon, K Tatsuno, B Wei - Advanced , 2022 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/adma.202109661 Tcr-epitope binding affinity prediction using multi-head self attention model M Cai, S Bang , H Lee - icml-compbio.github.iohttps://icml-compbio.github.io/2021/papers/WCBICML2021_paper_59.pdf Implementation of a dextramer staining approach to investigate antigen-specific CD8+ T cells LV Wipfler - 2022 - pub.fh-campuswien.ac.athttps://pub.fh-campuswien.ac.at/obvfcwhsacc/content/titleinfo/7638399/full.pdf HLA-A* 02 affinity to SARS-CoV-2 and susceptibility to COVID-19 LN Ribeiro, FS Sanches, VM Lelis - European Journal , 2023 - journals.tmkarpinski.comhttp://journals.tmkarpinski.com/index.php/ejbr/article/view/698 FASTMAP-a flexible and scalable immunopeptidomics pipeline for HLA-and antigen-specific T-cell epitope mapping based on artificial antigen-presenting cells L Weisbrod, L Capriotti, M Hofmann, V Spieler - Frontiers in , 2024 - frontiersin.orghttps://www.frontiersin.org/articles/10.3389/fimmu.2024.1386160/full Harnessing SARS-CoV-2-specific CD8+ T cells to kill target tumor cells for cancer immunotherapy K Jung, DH Ko, JY Jang, YR Kim, JY Heo - Cancer , 2024 - ncbi.nlm.nih.govhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10794008/ Prediction of SARS-CoV2 spike protein epitopes reveals HLA-associated susceptibility JP Romero-Lopez , M Carnalla-Cortes - Res , 2020 - scholar.archive.orghttps://scholar.archive.org/work/ggqtrb3qyfdnzcwdtjfxcbexge/access/wayback/https://assets.researchsquare.com/files/rs-25844/v1.pdf Development of multi-epitope peptide-based vaccines against SARS-CoV-2 HX Lim , J Lim , SD Jazayeri , S Poppema , CL Poh - Biomedical Journal, 2021 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S2319417020301530 Molecular mimicry of SARS-COV-2 antigens as a possible natural anti-cancer preventive immunization C Ragone, A Mauriello, B Cavalluzzo - Frontiers in , 2024 - frontiersin.orghttps://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1398002/abstract SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8+ T cell responses B Agerer , M Koblischke, V Gudipati - Science , 2021 - science.orghttps://www.science.org/doi/abs/10.1126/sciimmunol.abg6461 Development of a New Off-the-Shelf Plasmacytoid Dendritic Cell-Based Approach for the Expansion and Characterization of SARS-CoV-2-Specific T Cells A Maino, A Amen, J Plumas, L Bouquet - The Journal of , 2024 - journals.aai.orghttps://journals.aai.org/jimmunol/article-pdf/212/5/825/1653432/ji2300704.pdf
Chemical properties
Technical inquiry about: 3D-PP49306 H-YLQPR^TFLL-OH
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
